Preparation of biodegradable microspheres and matrix devices containing naltrexone

AAPS PharmSciTech

Volumn 4, Issue 3, 2003, Pages

  Dinarvand, Rassoul ^a   Moghadam, Shadi H ^a   Mohammadyari Fard, Leyla ^a   Atyabi, Fatemeh ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Matrix devices; Microspheres; Naltrexone; Poly(L lactide); Solvent evaporation

Indexed keywords

MICROSPHERE; NALTREXONE; POLYLACTIDE;

ANALYTICAL PARAMETERS; ARTICLE; BIODEGRADABILITY; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SYNTHESIS; EMULSION; EVAPORATION; FORCE; IN VITRO STUDY; MICROENCAPSULATION; PARTICLE SIZE; SCANNING ELECTRON MICROSCOPY; SURFACE PROPERTY; TABLET COMPRESSION; TABLET MATRIX; TABLET SURFACE; TEMPERATURE MEASUREMENT;

EID: 23144445495     PISSN: 15309932     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/pt040334     Document Type: Article

References (36)

1. Bullingham RE, McQuay HJ, Moore RA. Clinical pharmacokinetics of narcotic agonist-antagonist drugs. Clin Pharmacokinet. 1983; 8:332-343.
2. Way WL, Fields HL, Way EL. Opioid analgesics and antagonists. In: Katzung BG, ed. Basic and Clinical Pharmacology. 7th ed. Norwalk, CN: Appleton and Lange; 1998:512-513.
3. Chiang CN, Holister LE, Kishimoto A, Barnett G. Kinetics of naltrexone, sustained release preparations. Int J Clin Pharmacol Ther. 1984; 36:704-708.
4. Wise DL. Controlled release for use in treatment of narcotic addiction. In: Langer, RS, Wise DL, eds. Medical Application of Controlled Release. Vol 2. Boca Raton, FL: CRC Press; 1984:108-112.
5. Medical Economics staff. Production Information: Trexan. In: Physicians' Desk Reference. 53rd ed. Montvale, NJ: Medical Economics Co Inc; 1999:936-938.
6. Oslen JL, Knel FA. A review of parenteral sustained release naltrexone systems. In: Willet RE, Barnett G, eds. NIDA Research Monograph No. 28. Washington DC: DHHS; 1981:187-193.
7. Sharon AC, Wise DL. Development of drug delivery systems for use in treatment of narcotic addiction. In: Willet RE, Barnett G, eds. NIDA Research Monograph No. 28. Washington DC: DHHS; 1981:194-213.
8. Roskos KV, Tefft JA, Fritzinger BK, Heller H. Development of a morphine-triggered naltrexone delivery system. J Control Release. 1992; 19:145-160.
9. Bodmier R, McGinity JW. The preparation and evaluation of drug-containing poly(dl-lactide) microspheres formed by the solvent evaporation method. Pharm Res. 1987; 4:465-471.
10. Maa YF, Heller J. Controlled release of naltrexone pamoate from linear poly(ortho esters). J Control Release. 1990; 14:21-28.
11. Misra AL, Pontani RB. An improved long-acting delivery system for narcotic antagonists. J Pharm Pharmacol. 1978; 30:325-326.
12. Nitsch MJ, Banakar UV. Implantable drug delivery. J Biomater Appl. 1994; 8:247-265.
13. Pechnick RN, Terman GW. The role of opiate receptors in the potentiation of pentobarbital sleeping time by the acute and chronic administration of opiates. Neuropharmacology. 1987; 26:1589-1593.
14. Bardo MT, Neisewander JL. Chronic naltrexone supersensitizes the reinforcing and locomotor-activating effects of morphine. Pharmacol Biochem Behav. 1987; 28:267-273.
15. Bardo MT, Neisewander JL, Ennis RB. Chronic treatment with naltrexone enhances morphine-stimulated dopamine neurotransmission: neurochemical and behavioural evidence. Neuropharmacology. 1988; 27:1103-1109.
16. Yamaguchi K, Anderson JM. Biocompatibility studies of naltrexone sustained release formulations. J Control Release. 1992; 19:299-314.
17. Martin WR, Harris LS, Dewey WL. Naltrexone zinc tannate: a prolonged-action narcotic antagonist complex. J Pharm Sci. 1974; 63:159-161.
18. Negishi N, Bennet DB, Cho C, Jeong SY, Van Heeswijk WAR, Feijen J, Kim SW. Coupling of naltrexone to biodegradable poly(α-amino acids). Pharm Res. 1987; 4:305-310.
19. Sidman KR, Schwope AD, Steber WD, Rudolph SE. Use of synthetic polypeptides in the preparation of biodegradable delivery systems for narcotic antagonists. In: Willet RE, Barnett G, eds. NIDA Research Monograph No. 28. Washington DC: DHHS; 1981:214-231.
20. Tefft JA, Roskos KV, Heller J. The effect of lipase on the release of naltrexone from triglyceride-coated cellulose acetate phthalate microspheres. J Biomed Mater Res. 1992; 26:713-724.
21. Nakayama GR, Roskos KV, Fritzinger BK, Heller J. A study of reversibly inactivated lipases for use in a morphine-triggered naltrexone delivery system. J Biomed Mater Res. 1995; 29:1389-1396.
22. Bhargava HN, Matwyshyn GA, Gerk PM, et al. Effects of naltrexone pellet implantation on morphine tolerance and physical dependence in the rat. Gen Pharmacol. 1994; 25:149-55.
23. Chiang CN, Hollister LE, Gillespie HK, Foltz RL. Clinical evaluation of a naltrexone sustained release preparation. Drug Alcohol Depend. 1985; 16:1-8.
24. Yang Q, Owusu-Ababio G. Biodegradable progesterone microsphere delivery system for osteoporosis therapy. Drug Dev Ind Pharm. 2000; 26:61-70.
25. Tamilvanan S, Sa B. Studies on the in vitro release characteristics of ibuprofen loaded microspheres. J Microencapsul. 2000; 17:57-67.
26. Capan Y, Woo BH, Gebrekidan S, Ahmed S, DeLuca PP. Influence of formulation parameters on the characteristics of poly(D,L-lactide-co-glycolide) microspheres containing poly(L-lysine) complexed plasmid DNA. J Control Release. 1999; 60:279-286.
27. Ravivarapu HB, Lee H, DeLuca PP. Enhancing initial release of peptide from poly(d,l-lactide-co-glycolide) (PLGA) microspheres by addition of a porosigen and increasing drug load. Pharm Dev Technol. 2000; 5:287-296.
28. Cardinal JR. Matrix systems. In: Langer RS, Wise DL, eds. Medical Applications of Controlled Release Systems. Vol 1. Boca Raton, FL: CRC Press Inc; 1984:43-44.
29. Song SZ, Cardinal JR, Kim SH, Kim SW. Progestin permeation through polymer membranes, V: progesterone release from monolithic hydrogel devices. J Pharm Sci. 1981; 70:216-221.
30. Soppimath KS, Kulkarn AR, Aminabhavi TM. Encapsulation of antihypertensive drugs in cellulose-based matrix microsphere: characterization and release kinetics of microspheres and tableted microspheres. J Microencapsul. 2001; 18:397-405.
31. Schmitt EA, Flanagan DR, Linhardt RJ. Degradation and release properties of pellets fabricated from three commercial poly(DL-lactide-co-glycolide) biodegradable polymers. J Pharm Sci. 1993; 82:326-329.
32. Migliaresi C, Cohn D, De Lollis A. Dynamic mechanical and calorimetric analysis of compression molded PLLA of different molecular weights: effects of thermal treatments. J Appl Polymer Sci. 1991; 43:83-95.
33. Dinarvand R, Imani M, Ryahipoor F, Atyabi F. Preparation of a biodegradable matrix system for contraceptive drug delivery. Drug Delivery Sys Sci. 2001; 1:73-76.
34. Cohn D, Younes H, Marom G. Amorphous and crystalline morphologies in glycolic acid and lactic acid polymers. Polymer. 1987; 28:2018-2022.
35. Gilding DK, Reed AM. Biodegradable polymers for use in surgery: polyglycolic acid/poly(lactic acid) homo- and copolymers. Polymer. 1979; 20:1459-1464.
36. Omelczuk MO, McGinity JW. The influence of polymer glass transition temperature and molecular weight on drug release from tablets containing Poly(DL-lactic acid). Pharm Res. 1992; 9:26-32.